Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of multiple doses of PAINLESS Nerve Growth Factor CHF6467 in paediatric subjects with optic pathway glioma
2024-515753-16-00Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in optic nerve glioma (OPG) comparing CHF6467 (recombinant nerve growth factor R100E) with Placebo (2 arms). Primary endpoint: Largest radius of the visual field. Started May 2023; status: completed.
02
Drugs
recombinant nerve growth factor R100E
03
Conditions
optic nerve glioma (OPG)
Beyond the preview
Go deeper on 2024-515753-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515753-16-00.